Drug news
Otsuka to market Iclusig in Japan, S.Korea, China and SE Asia.
Ariad Pharma and Otsuka Pharmaceutical Co., Ltd. announced that they have entered into an agreement for Otsuka to commercialize Iclusig (ponatinib) in Japan and nine other Asian countries and to fund future clinical trials in those countries. In addition to Japan, the other Asian countries that are included in this agreement are China, South Korea, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins